Annoroad, a Chinese gene-sequencing firm, has raised $105m in a series C funding round led by Ping An Ventures and Shenzhen GTJA Investment Group. The company is developing an automated DNA sequencer that can sequence up to 100,000 genomes per hour. Beijing-based Annoroad is recognised for its fertility and tumour test products, and is one of the largest genomics companies in China. The funds will be used to develop the company's overseas business connections, improve its R&D efforts and hire further staff. In 2015, Annoroad announced plans to co-develop a prenatal DNA diagnostic with Illumina, combining the American company’s sequencing technology with its own nucleic acid extraction and data analysis. Some funding will be used for its SolarGenomics subsidiary, which offers a cloud-based platform for the storage of bioinformatics and research.
Annoroad, a Chinese gene-sequencing firm, has raised $105m in a series C funding round led by Ping An Ventures and Shenzhen GTJA Investment Group. The company is developing an automated DNA sequencer that can sequence up to 100,000 genomes per hour. Beijing-based Annoroad is recognised for its fertility and tumour test products, and is one of the largest genomics companies in China. The funds will be used to develop the company's overseas business connections, improve its R&D efforts and hire further staff. Some funding will be used for its SolarGenomics subsidiary, which offers a cloud-based platform for the storage of bioinformatics and research.